血友病RNA治疗创新
综述指出,鉴于现有因子、非因子及腺相关病毒基因疗法的不足,RNA治疗正在改变血友病管理方式。从敲低凝血调节物抗凝血酶、蛋白S和肝素辅因子II的小干扰RNA,到可能实现个体化治疗的CRISPR/Cas9基因编辑,这些新技术有望减少出血和因子使用并避免抑制物形成。部分药物处于临床前研究,部分处于早期试验,有简化治疗、改善止血和生活质量的潜力。
要点
- RNA治疗通过敲低抗凝血酶、蛋白S和肝素辅因子II等凝血调节物或基因编辑来改变血友病管理。
- 小干扰RNA和CRISPR/Cas9基因编辑等新技术有减少出血和因子使用、避免抑制物形成的潜力。
- 部分RNA药物处于临床前研究,部分处于早期试验,未来可能简化治疗并改善止血和生活质量。
核心结论
- RNA治疗为血友病管理带来新思路,部分药物处于临床前或早期试验阶段,有简化治疗、改善止血和生活质量的潜力。
- 这些疗法通过操纵凝血级联和凝血酶生成及其调节,将加深对止血和血栓形成的理解,并最终为遗传性出血性疾病患者带来更好的疗法。
- 随着临床前新技术的发展,未来有望减少关节出血、致残性关节病和骨科手术,并改善身心健康。
研究设计与样本
- 综述,总结当前血友病治疗局限及新型RNA治疗进展,包括信使RNA纳米颗粒递送和基因编辑。
主要发现
- 小干扰RNA可敲低凝血调节物抗凝血酶、蛋白S和肝素辅因子II。
- CRISPR/Cas9基因编辑可能实现个体化治疗。
- 部分RNA药物处于临床前研究,部分处于早期试验。
关键数值与推荐
- 小干扰RNA靶点包括抗凝血酶、蛋白S和肝素辅因子II。
- 综述涉及信使RNA纳米颗粒递送和基因编辑技术。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Given the shortcomings of current factor-, nonfactor-, and adeno-associated virus gene-based therapies, the recent advent of RNA-based therapeutics for hemophilia is changing the fundamental approach to hemophilia management. From small interfering RNA therapeutics that knockdown clot regulators antithrombin, protein S, and heparin cofactor II, to CRISPR/Cas9 gene editing that may personalize treatment, improved technologies have the potential to reduce bleeds and factor use and avoid inhibitor formation. These novel agents, some in preclinical studies and others in early phase trials, have the potential to simplify treatment and improve hemostasis and quality of life. Furthermore, because these therapies arise from manipulation of the coagulation cascade and thrombin generation and its regulation, they will enhance our understanding of hemostasis and thrombosis and ultimately lead to better therapies for children and adults with inherited bleeding disorders. What does the future hold? With the development of novel preclinical technologies at the bench, there will be fewer joint bleeds, debilitating joint disease, orthopedic surgery, and improved physical and mental health, which were not previously possible. In this review, we identify current limitations of treatment and progress in the development of novel RNA therapeutics, including messenger RNA nanoparticle delivery and gene editing for the treatment of hemophilia.
引用
- Ragni MV, Chan SY. Innovations in RNA therapy for hemophilia. Blood. 2023. PMID: 37478403. doi:10.1182/blood.2022018661
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。